Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-DB8
- Development stage
- Phase 2
- Lead developer
- Cancer Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The drug [99mTc]Tc-DB8 is a technetium-99m labeled radiopharmaceutical currently being investigated for diagnostic imaging of gastrin releasing peptide receptors (GRPRs). It is specifically being studied in patients with prostate cancer and breast cancer. It consists of technetium-99m, a common radioisotope in nuclear medicine with a 6-hour half-life and suitable gamma emission for SPECT imaging, and a peptide component (DB8) designed to target GRPRs, which are overexpressed in certain cancers. The primary objectives of the ongoing clinical trial (NCT05940298) include assessing the distribution and dosimetry of [99mTc]Tc-DB8 in normal tissues and tumors, as well as evaluating its safety and tolerability. Secondary objectives involve comparing SPECT imaging results with other modalities like CT, MRI, ultrasound, and immunohistochemistry in prostate and breast cancer patients.
- Brand names
- technetium-99m db8technetium99m db8technetium 99m db8
- Other names
- Tc-99m-DB8Tc99m-DB8Tc 99m-DB8DB8DB-8DB 8
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on [99mTc]Tc-DB8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]Tc-DB8.